ABSTRACT

The active metabolite of azathioprine, 6-thioguanine nucleotide (6-TGN) is the main component responsible for the immunosuppressive effect in treatment of inflammatory bowel disease (IBD).

The aim of this study was to assess the correlation between the concentration of 6-thioguanine nucleotide and disease activity, azathioprine-related adverse effects and time duration of treatment in patients with inflammatory bowel disease.

Thirty-four patients were included in this study. Type of disease, gender, time duration of therapy and adverse effects were recorded. Metabolite concentration was determined by high performance liquid chromatography.

Twenty-one percent of patients have experienced an adverse effect, with leucocytopenia most commonly occurring (42.9%). More adverse effects were registered when patients were treated with azathioprine in a period of less than 3 months in comparison to the group of patients that have been under therapy between 3-12 months and more than 12 months (p<0.05). Most of the patients that presented any adverse effect had high 6-TGN concentration (>450 pmol/8x10^8 Er). The mean value of 6-TGN metabolite concentration in IBD patients treated with azathioprine was 437.46 pmol/8x10^8 Er ± 198.82 pmol/8x10^8. The time duration of azathioprine treatment did not have any significant impact on the achieved 6-TGN concentration (p>0.05). Twenty patients (58.9%) had achieved remission after therapy initiation with azathioprine.

More alertness is recommended to clinicians towards patients in the first 3 months of the therapy. Our study demonstrated that higher 6-TGN concentration is associated with azathioprine toxicity.

Keywords: Inflammatory bowel disease, 6-Thioguanine nucleotide, azathioprine
detection that do not respond positively to therapy, and/or are dosed suboptimally and in case when pre-dominant methylation exists. In addition, 6-TGN concentration may predict dose-depended toxicity in a way that the side effects might be avoided. [2,5]

Up to now, there are no data available whether 6-TGN concentration measurement could improve the clinical outcome of IBD patients that are on continuous AZA treatment both in terms of efficacy and safety.

The main motive of our research was to investigate the impact of 6-TGN monitoring on further therapeutic decisions in IBD patients. Specifically, we have assessed the correlation between 6-TGN metabolite concentration and disease activity, AZA-related AE’s and time duration of AZA treatment in patients with IBD.

**MATERIAL AND METHODS**

**Data collection**

The study was conducted at the National Center for monitoring of IBD patients at the University Clinic of gastroenterohepatology in Skopje (Macedonia).

All patients with IBD who had been prescribed AZA were identified via a prospective electronic database maintained by IBD clinician specialists. Thirty-four (34) patients were called to come to the clinic at a specified time.

The following variables were recorded: type of IBD (Chron’s disease or Ulcerative colitis), gender, AZA duration treatment, determination of 6-TGN concentration with data of AZA dose (mg) when blood sample was collected and possible AE’s were registered, as well.

Three groups of patients were identified regarding the time duration of AZA treatment (less than 3 months, between 3-12 months and more than 12 months). Most of the patients (53%) in this study have used AZA in a period between 3 and 12 months. Disease activity was assessed using Crohn’s Disease Activity Index (CDAI) and Ulcerative Colitis Activity Index (UCAI).

**Quantification of 6-TGN metabolite**

6-TGN concentration was determined in patients’ blood after at least 3 months from the onset of AZA therapy. Full blood was taken from 15 healthy volunteers and 32 patients with IBD who were at least 3 months on treatment with AZA.

Blood samples (5 mL) were collected in test tubes containing heparin and centrifuged at 4 °C, in order to separate the red blood cells from the whole blood. Then, the red blood cells were settled down to the bottom and the supernatant rich in platelets, as well as the upper layer of cells (leukocytes and platelets) was removed. The RBC concentration in each of the tubes were normalized to $4 \times 10^9$ erythrocytes. The samples were stored at -80 °C until HPLC analysis. To achieve that, 500 μL sample was placed in a tube with 5 mg of the internal standard dithiothreitol (DTT), and 50 μL perchloric acid was added for deproteinization. Samples were then centrifuged at a 3000 rpm, 15 minutes at 4 °C in order to generate derivatization. Subsequently, the supernatant, the acid extract, was separated and heated for 45 minutes at a temperature of 100 °C, resulting in hydrolysis of the thiopurine nucleotides in free bases. These prepared samples after cooling were injected to the HPLC column, Zorbax Eclipse XDB C18 column, 150 x 4.5mm, 5 μm, (Agilent Technologies).

The values obtained for 6-TGN concentrations were categorized into three groups, subtherapeutic (<200 pmol / $8 \times 10^8$ Er), therapeutic (200-400 pmol / $8 \times 10^8$ Er) and high (> 400 pmol / $8 \times 10^8$ Er).

**Ethical aspects**

This study was performed in accordance with the principles of the Declaration of Helsinki, Brazil. [6] The study has been approved by the Ethical committee of the Faculty of Medicine in Skopje, University of Ss. Cyril and Methodius.

**STATISTICAL ANALYSIS**

Statistical analysis was performed using SPSS for Windows, version 17 (USA). The Fisher-Freeeman-Halton exact test was used to determine the association between certain characters in group of patients. The Sperman Rang Order Correlation test was used to determine the correlation between two variables.

In order to test the significance of the difference between certain analyzed parameters, depending on the type and distribution of data, the parametric Student’s t-test and ANOVA as well as nonparametric tests for independent samples (Mann Whitney U test) were used. A level of $p \leq 0.05$ was considered statistically significant.
RESULTS

Demographic characteristics

Thirty-four (34) patients with IBD, of which 22 (64.7%) with Crohn’s disease and 12 (35.3%) with Ulcerative colitis were included in this study. The analysis showed no statistically significant difference between the two clinical types of the disease in relation to the gender of the patients (p > 0.05). The average age of included patients was 40.84 ± 12.26 years with a minimum age of 15 and a maximum age of 66 years. A higher average age was seen in patients with Crohn’s disease when compared with patients with Ulcerative colitis (p < 0.05, t-test).

Adverse outcomes

A total of 7 patients (21%) have experienced adverse effects. The most commonly occurring AE was leukocytopenia (42.9%), followed by elevated transaminases (28.6%), aphthous ulcers (14.3%) and elevated alpha amylase in serum (14.3%). More AE’s were registered in the group of patients that have used AZA in a period of less than 3 months when compared with the group of patients that have used AZA between 3-12 months and more than 12 months (p <0.05) (Table 1).

<table>
<thead>
<tr>
<th>Time duration of AZA treatment (months)</th>
<th>AZA related AE’s</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>&lt; 3</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>3 - 12</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>&gt;12</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>Total</td>
<td>7</td>
<td>27</td>
</tr>
</tbody>
</table>

6-TGN concentration

6-TGN concentration was measured only in patients that were treated with AZA in a period of more than 3 months (N=32). The average 6-TGN concentration in patients with IBD treated with AZA was 437.46 pmol/8x10⁸ Er ± 198.82 pmol/8x10⁸ Er (min. 64.8 pmol/8x10⁸ Er and max. 905.5 pmol/8x10⁸ Er). Fifty percent of the patients (50%) had 6-TGN values above 399.8 pmol/8x10⁸ Er.

Patients treated with AZA between 3 to 12 months had average 6-TGN concentration of 460.06 pmol/8x10⁸ Er ± 206.61 pmol/8x10⁸ Er (min. 64.8 pmol/8x10⁸ Er, max. 905.5 pmol/8x10⁸ Er). Fifty (50%) percent of these patients had 6-TGN value above 427.9 pmol/8x10⁸ Er.

The range for 6-TGN in the group of patients that were under AZA treatment more than 12 months was between 205.1 pmol/8x10⁸ Er and 746.4 pmol/8x10⁸ Er, average concentration of 404.42 pmol/8x10⁸ Er ± 189.99 pmol/8x10⁸ Er. Fifty (50%) percent of these patients had 6-TGN value above 361.5 pmol/8x10⁸ Er.

The time duration of AZA treatment did not affect the concentration of achieved 6-TGN metabolite (p >0.05).

6-TGN concentration and time duration of AZA treatment

An additional analysis of 6-TGN metabolite concentration was performed, where patients were divided in 3 groups i.e., group 1 with subtherapeutic values of 6-TGN (<200 pmol/8x10⁸ Er); group 2 with therapeutic values of 6-TGN (200-400 pmol/8x10⁸ Er) and group 3 with high values of 6-TGN (>400 pmol/8x10⁸ Er).

Most of the patients (57.89%) that have used AZA in a period between 3-12 months belonged to group 3 (high 6-TGN concentration), 31.58% belonged to group 2 (therapeutic 6-TGN concentration) and 10.53% belonged to the subtherapeutic group 1 (p>0.05).

Our analyzes demonstrated that in the group of patients treated with AZA in a period of more than 12 months, 61.54% were in the therapeutic range of 6-TGN and 38.46 % had high concentration values of 6-TGN. No patient was found to be in the subtherapeutic group (group 1) (p>0.05).

6-TGN concentration and adverse effects

Patients who were treated with AZA and where AE’s were registered had higher mean value of 6-TGN when compared with those patients where no AE’s were noticed (487.54 pmol/8x10⁸ Er ± 185.57 pmol/8x10⁸ Er vs. 429.11 pmol/8x10⁸ Er ± 203.39 pmol/8x10⁸ Er (t-test, p>0.05).

Fifty (50%) percent of patients with AE’s had average value of 6-TGN concentration above 562.8 pmol/8x10⁸ Er, compared with the group of patients who did not present AE’s, where average
value for 6-TGN concentration in 50% of them was 399.5 pmol/8x10^8 Er (Figure 1).

Most of the patients that presented any AE had high 6-TGN concentration (group 3) where 6-TGN concentration was above 450 pmol/8x10^8 Er. None of the patient who had subtherapeutic 6-TGN concentration (group 1) had presented AE (Table 2).

<table>
<thead>
<tr>
<th>6-TGN concentration</th>
<th>AE</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Group 1 Subtherapeutic &lt;200 pmol / 8x10^8 Er</td>
<td>Number 0</td>
<td>2</td>
</tr>
<tr>
<td>Group 2 Therapeutic 200-400 pmol / 8x10^8 Er</td>
<td>Number 2</td>
<td>12</td>
</tr>
<tr>
<td>Group 3 high &gt; 400 pmol / 8x10^8 Er</td>
<td>Number 3</td>
<td>13</td>
</tr>
<tr>
<td>Total</td>
<td>Number 5</td>
<td>27</td>
</tr>
</tbody>
</table>

Fisher-Freeman-Halton exact test: p=0.9999
*statistically significant for p&lt;0.05

6-TGN concentration and disease activity

From 34 patients treated with AZA in this study, remission was registered in 20 (58.9%) of them. The rest 14 patients (41.2%) remained in acute phase of the disease. No statistical significance was found between the two types of the disease (Crohn’s disease vs. Ulcerative colitis) regarding the percent of patients that have achieved remission (13 patients (59.1%) vs. 7 patients (58.3%)).

As 6-TGN metabolite concentration increased, the probability of remission rose (p&gt;0.05; R=0.0819) (Figure 2a).

6-TGN concentration, AZA dose (mg) and AE’s

Average AZA dose at the moment of blood sample collection for determination of 6-TGN concentration was 164.7 ± 27.3 mg (min.100 mg; max.200 mg). Fifty (50) percent of the patients had received AZA dose above 200 mg. The performed analysis for the association between AZA dose and 6-TGN concentration showed the existence of a linear indirect correlation (R = -0.2405). As the dose of AZA was increasing, the concentration of 6-TGN metabolite was reduced (Figure 2b). Higher dose of AZA was found to be administered in patients who did not present any AE in comparison with the group of patients where AE’s were
registered (168 ± 25.4 mg, min.100 mg, max.200 mg vs. 146.6 ± 30.4 mg, min. 125 mg, max.200 mg), (t-test, p=0.0489).

DISCUSSION

In the clinical practice, 25% of patients may not respond to AZA or 6-MP, 30% may experience relapse during treatment, while 15-30% of patients may develop adverse effects (7).

Herein we presented that monitoring of AZA metabolites can predict the clinical response in patients with IBD, and thus individualize therapeutic treatment.

Twenty-one (21) percent of patients who were on AZA therapy at the time of this study (N = 34), experienced adverse effects. Similar results were reported by Saibeni et al., 27.4% (8). The literature data show, bone marrow suppression in 2-5% of cases in IBD patients treated with thiopurine and leucocytopenia in 2-4% of the patients treated with AZA or 6-MP (9). Pancreatitis occurs in about 4% of patients treated with thiopurine, usually in the first weeks of starting the treatment (10).

Data from our study support these findings where leukocytopenia was the most common seen AE in our patients (42.9%). Our study also demonstrated significant differences in the duration of AZA therapy (less than 3 months, between 3-12 months and > 12 months) and the number of reported adverse effects (100% vs 16.7% versus 14.3 %), p <0.05. Intolerance to AZA appears at lower initial doses, after which the drug is either excluded, or if possible, the dose is decreased (11). Our results showed a difference in the average value of AZA doses, in addition to a higher dose of the drug in the group of patients not having adverse effects compared to the group of patients who reported adverse effects (168 mg ± 25.4 mg v.s 146.6 mg ± 30.4 mg) (p <0.05).

Azathioprine has a slow effect, with a half time to achieve a therapeutic response of 3 months. The long time required to achieve the therapeutic response is thought to correlate with the accumulation of 6-TGN and the attainment of a steady-state condition. In adults with CD, the half time to achieve steady-state of the 6-TGN metabolite is 5 weeks (12).

The highest percentage of adverse effects was registered in patients with high concentration of 6-TGN (18.75%), followed by the group of therapeutic concentration (14.29%). High concentration of 6-TGN is associated with an increased occurrence of leucocytopenia, lymphopenia, and the use of mesalazine (13). In a study by Lee et al. (13), the occurrence of leucocytopenia (p = 0.025) and lymphopenia (p = 0.045) are associated with high concentrations of 6-TGN.

No statistical significance was found between the dose of AZA and the concentration of 6-TGN (p>0.05). Literature data are contradictory. Zhang et al., (14) and Gearry et al., (15) confirm our results in their studies, but in the study by Lee et al. (13) a positive correlation was found between the dose of AZA and concentration of 6-TGN (p <0.0001). Some factors may influence the acceleration of 6-TGN pharmacokinetics. Changes in azathioprine absorption or interactions with other drugs such as mesalazine, balsalazide and sulphasalazine are associated with increasing the 6-TGN concentration in red blood cells (16,17). Also, the lack of method standardization for concentration determination of 6-TGN may be one of the reasons for these contradictory results.

Fraser et al. (18) demonstrated the safety and efficacy of AZA in the treatment of IBD. The long-term outcome of treatment with thiopurines in IBD patients in real life has so far been studied in several observational studies. The percentage of patients who achieved remission after thiopurine use was recorded in the studies of Saibeni et al., (46.6%) and Fraser et al., (45% CD, 58% UC) (8,18). These data are in line with our results, which showed that following treatment with AZA, 58.9% of patients achieved remission.

CONCLUSION

The majority of the AE’s were reported at the beginning of the treatment with AZA, hence more alertness is recommended to clinicians towards these patients in the first 3 months of initiation of the therapy. Our study suggested that higher 6-TGN concentration is associated with azathioprine toxicity. Studies, with larger sample of patients are needed to investigate the exact mechanism of 6-TGN in IBD patients treated with AZA.
Conflict of interest statement
I have nothing to disclose.

Acknowledgements
Authors would like to thank Maja Slaninka Miceska, Petranka Mishevska and Nikola Labachevski for scientific proposals and critical review of the manuscript.

REFERENCES

Резиме

ВАЖНОСТА НА МОНИТОРИРАЊЕ НА 6-ТИОГВАНИН НУКЛЕОТИД МЕТАБОЛИТ КАЈ ПАЦИЕНТИ СО ВОСПАЛИТЕЛНИ ЦРЕВНИ ЗАБОЛУВАЊА ТРЕТИРАНИ СО АЗАТИОПРИН

Кристина Павловска¹, Марија Петрушевска¹, Калина Џорѓиевска¹, Драгица Џенделовска¹, Јасмина Тоник Рибарска¹, Џеанана Лабачевска Ѓатовска³, Емилија Атанасовска¹

¹ Институт за претклиничка и клиничка фармакологија со токсикологија, Медицински факултет, Скопје, Република Македонија
² Фармацевтски факултет, Скопје, Република Македонија
³ Институт за микробиологија и паразитологија, Медицински факултет, Скопје, Република Македонија

Активниот метаболит на азатиоприн — 6-тиогванин нуклеотид (6-TGN) е главната компонента што е одговорна за имуносупресивниот ефект на лекот во третманот на пациентите со воспалителни цревни забољувања (ВЦЗ).

Целта на оваа студија беше да се процини поврзаноста меѓу концентрацијата на 6-тиогванин нуклеотид и активноста на болеста, несаканите реакции поврзани со употребата на азатиоприн и времетраењето на третманот кај пациентите со ВЦЗ.

Во оваа студија беа вклучени триесет и четири пациенти. Регистрирани беа: клиничкиот тип на болеста, полот, времетраењето на терапијата со азатиоприн и несаканите реакции. Концентрацијата на 6-тиогванин нуклеотид беше определена со употреба на методата HPLC (high performance liquid chromatography), која за оваа цел првпат беше поставена во Република Македонија.

Кај двесет и еден процент од пациентите беше регистрирана несакана реакција. Најчешта несакана реакција беше леукоцитопенија (42,9 %). Поголем процент на несакани реакции беа регистрирани кај пациентите што беа третирани со азатиоприн во период пократок од три месеци, во споредба со групата пациенти што беше подложена на терапија во период од 3 до 12 месеци и повеќе од 12 месеци (p < 0,05). Најголемиот процент од пациентите кај кои беше регистрирана несакана реакција имаа висока 6-TGN концентрација (> 450 pmol / 8x10⁸ Er). Средната вредност на концентрацијата на 6-TGN метаболитот кај пациентите со ВЦЗ третирани со азатиоприн беше 437,46 pmol / 8x10⁸ Er ± 198,82 pmol / 8x10⁸. Времетраењето на третманот со азатиоприн не влијааше на постигнатата концентрација на 6-TGN (p > 0,05). Двесет пациенти (58,9 %) постигнаа ремисија по започнување на терапијата со азатиоприн.

На медицинскиот персонал што ординира терапија со азатиоприн му се препорачува особено внимание да посвети на пациентите во првите три месеци од започнувањето на терапијата. Нашата студија покажа дека високата концентрација на 6-TGN метаболит се поврзува со азатиопринска токсичност.

Ключни зборови: воспалителни цревни забољувања, 6-тиогванин нуклеотид, азатиоприн